The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 36, Issue 2, 2017, Pages 457-461

  Cuomo, Giovanna ^a,b   D’Abrsca, Virginia ^a   Iacono, Daniela ^a   Pantano, Ilenia ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Department of Internal and Experimental Medicine   (Italy)

Author keywords

Abatacept; Anti TNF; Latent tuberculosis; Quantiferon; Rheumatoid arthritis; Tocilizumab; Tuberculin test

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE ACTIVITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEX DIFFERENCE; SMOKING; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; VERY ELDERLY; ARTHRITIS, RHEUMATOID; COMPLICATION; INTERFERON GAMMA RELEASE ASSAY; ITALY; MIDDLE AGED; YOUNG ADULT;

ABATACEPT; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ITALY; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 84994508597     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3462-z     Document Type: Article

References (20)

1. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38(9):1261–1265
2. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122–2127
3. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, BIOBADASER Group et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766–1772
4. World Health Organization. Global tubercolosis report (2013) URL: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf
5. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53(10):1872–1885. doi:10.1093/rheumatology/keu172
6. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639. doi:10.1002/acr.21641
7. Vassilopoulos D, Tsikrika S, Hatzara C et al (2011) Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 18(12):2102–2108. doi:10.1128/CVI.05299-11
8. Keystone EC, Papp KA, Wobeser W (2011) Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol 38(7):1234–1243. doi:10.3899/jrheum.100623
9. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH (2009) Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 36(10):2158–2163. doi:10.3899/jrheum.090150
10. Sanduzzi A, Bocchino M, Atteno M et al (2012) Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl 89:82–85. doi:10.3899/jrheum.120252
11. Hatzara C, Hadziyannis E, Kandili A et al (2015) Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 74(10):1848–1853. doi:10.1136/annrheumdis-2014-205376
12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581
13. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tubercolosis infection. Am J Respir Crit Care Med 161:5221–5247
14. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee; Centers for Disease Control and Prevention (CDC) (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep 59(RR-5):1–25
15. Nobre CA, Callado MR, Lima JR, Gomes KW, Martiniano GV, Vieira WP (2012) Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients. Rheumatol Int 32(9):2769–2775. doi:10.1007/s00296-011-2017-5
16. Marques CDL, Duarte ALBP, Lorena VMB et al (2009) Resposta atenuada ao PPD no diagnostico de infection tuberculosa latente em pacientes com artrite reumatoide. Rev Bras Reumatol 49(2):121–131
17. Westhovens R, Yocum D, Han J, START Study Group et al (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54(4):1075–1086
18. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. Ann Rheum Dis 71(2):231–237. doi:10.1136/annrheumdis-2011-200489
19. Garcovich S, Ruggeri A, D'Agostino M et al (2012) Clinical applicability of quantiferon-TB-gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 26(12):1572–1576. doi:10.1111/j.1468-3083.2011.04220.x
20. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59(6):800–806. doi:10.1002/art.23705